Drugs in Dev. Musculoskeletal
Phase I
Canada 
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 21, 2023
Lead Product(s) : Cannabidiol,Cannabichromene,Tetrahydrocannabinol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial
Details : Trichomylin® softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate chronic pain and has the potential to be a safe and effective alternative to opioids – without the devasting addictive qualities
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : NM Clinical Research & Osteoporosis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
CBD in Postmenopausal Women With Osteopenia
Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bone Diseases, Metabolic.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : NM Clinical Research & Osteoporosis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Aureuspharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 27, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Aureuspharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Trichomylin
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Novotech | ZYUS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trichomylin is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Trichomylin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Novotech | ZYUS Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials
Details : ZYUS Life Sciences will be launching a first-in-human (FIH) clinical trial on the safety, tolerability and efficacy of its lead drug product candidate, Trichomylin®, through its wholly owned subsidiary, ZYUS Life Sciences Australia Pty. Ltd.
Product Name : Trichomylin
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myositis Ossificans.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2021
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myositis Ossificans.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2021
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP-104IAR
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Syreon Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis
Details : EP-104IAR is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : EP-104IAR
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Syreon Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
